Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of May 2025. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
| Metric | Value as of April 30, 2025 |
|---|---|
| Issued Share Capital | 4,315,241,378 Ordinary Shares (31.5 pence each) |
| Treasury Shares | 204,800,108 Ordinary Shares |
| Total Voting Rights | 4,110,441,270 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. It presents a static snapshot of share capital as of April 30, 2025, without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide clear values for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification intended to assist shareholders in calculating disclosure thresholds under FCA rules.
Important Facts for Investors
- The total number of voting rights is 4,110,441,270, which serves as the denominator for shareholder notification calculations.
- Approximately 204.8 million shares are held in Treasury and do not carry voting rights.
- Shareholders should notify the Company Secretary at company.secretary@gsk.com regarding changes in their interest.
- This filing contains no financial performance data or strategic updates.